



National Health (Pharmaceutical Benefits) Electronic National Residential Medication Charts Approval Instrument 2025

PB 48 of 2025

made under section 12A, paragraph 41(5)(b) and subsection 45(9) of the
National Health (Pharmaceutical Benefits) Regulations 2017

Compilation No. 1

Compilation date: 1 November 2025

Includes amendments: F2025N00906

Prepared by the Office of Parliamentary Counsel, Canberra

About this compilation

This compilation

This is a compilation of the *National Health (Pharmaceutical Benefits) Electronic National Residential Medication Charts Approval Instrument 2025* that shows the text of the law as amended and in force on 1 November 2025 (the *compilation date*).

The notes at the end of this compilation (the *endnotes*) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au).

Application, saving and transitional provisions

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Presentational changes

The *Legislation Act 2003* provides for First Parliamentary Counsel to make presentational changes to a compilation. Presentational changes are applied to give a more consistent look and feel to legislation published on the Register, and enable the user to more easily navigate those documents.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. Any modifications affecting the law are accessible on the Register.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

1	Name	1
3	Authority	1
4	Definitions.....	1
5	Prescribed requirements for electronic medication charts under the Regulations.....	1
Schedule 1 – Information Requirements		3
1.	Approved residential care home patients	3
2.	Allergies and Drug Reactions (ADRs)	3
3.	Clinical recordings and monitoring	4
5.	Period of validity	4
6.	PBS prescriber	4
7.	Regularly administered and short-term pharmaceutical benefits	4
8.	Insulin pharmaceutical benefits (non-Pro Re Nata) (non-PRN)	6
9.	Insulin PRN (as required) pharmaceutical benefits	7
10.	PRN (as required) pharmaceutical benefits	7
11.	Variable dose pharmaceutical benefits (non-insulin)	8
12.	Infusion pharmaceutical benefit additional requirements	10
13.	Transdermal Patch pharmaceutical benefit additional requirements	10
14.	Schedule 8 (controlled) pharmaceutical benefits additional requirements	10
15.	Nutritional supplements pharmaceutical benefits	10
Schedule 2 – System Functionality		12
1.	Approved residential care home patients	12
2.	Allergies and Drug Reactions (ADRs)	12
3.	Period of validity	12
4.	PBS prescriber	12
5.	Regularly administered and short-term pharmaceutical benefits	13
6.	Insulin pharmaceutical benefits (non-PRN)	13
7.	PRN (as required) pharmaceutical benefits	13
8.	Variable dose pharmaceutical benefits (non-insulin)	13
9.	Infusion pharmaceutical benefits	13
10.	Schedule 8 (controlled) pharmaceutical benefits	13
11.	Security and Validation	14
12.	Additional System Functionality	14

Schedule 3 – Copy of an Electronic Medication Chart	15
1. Approved residential care home patients	15
2. Allergies and Drug Reactions (ADRs)	15
3. Approved residential care homes	15
4. Current Pharmaceutical Benefits	16
5. Recently Ceased Pharmaceutical Benefits	17
6. Pharmaceutical Benefit Administration	17
7. Nutritional Supplements	17
8. Period of validity	17
9. Medication Chart and Medication Chart Order Identification	18
Endnotes	19
Endnote 1—About the endnotes	19
Endnote 2—Abbreviation key	20
Endnote 3—Legislation history	21
Endnote 4—Amendment history	22

1 Name

- (1) This instrument is the *National Health (Pharmaceutical Benefits) Electronic National Residential Medication Charts Approval Instrument 2025*.
- (2) This instrument may also be cited as PB 48 of 2025.

3 Authority

This instrument is made under section 12A, paragraph 41(5)(b) and subsection 45(9) of the *National Health (Pharmaceutical Benefits) Regulations 2017*.

4 Definitions

Note: A number of expressions used in this instrument are defined in subsection 5(1) of the Regulations, including the following:

- (a) authority approval number;
- (b) electronic medication chart;
- (c) electronic medication chart system.

In this instrument:

approved residential care home has the same meaning as in the *Aged Care Act 2024*.

PBS prescriber has the same meaning as in Part VII of the *National Health Act 1953*.

pharmaceutical benefit has the same meaning as in Part VII of the *National Health Act 1953*.

pharmaceutical benefits scheme (PBS) has the same meaning as in Part VII of the *National Health Act 1953*.

Regulations means the *National Health (Pharmaceutical Benefits) Regulations 2017*.

repatriation pharmaceutical benefit (RPBS) has the same meaning as in Part VII of the *National Health Act 1953*.

residential care means funded aged care services accessed through the service group residential care (within the meaning of the *Aged Care Act 2024*).

5 Prescribed requirements for electronic medication charts under the Regulations

- (1) Schedule 1 – Information Requirements provides the approved information requirements that must be met in relation to an electronic medication chart. Schedule 1 is only for the purposes of an electronic medication chart that is used for prescribing, supplying and recording the administration of, pharmaceutical benefits to persons receiving treatment in or at an approved residential care

Section 5

home. The approved information requirements are made under paragraph 41(5)(b) of the Regulations.

- (2) Schedule 2 – System Functionality provides the approved electronic medication chart system functionality requirements to facilitate the safe and effective prescribing and supplying of pharmaceutical benefits using electronic medication charts. Schedule 2 is only for the purposes of an electronic chart that is used for prescribing, supplying and recording the administration of, pharmaceutical benefits to persons receiving treatment in or at an approved residential care home. The approved electronic medication chart system functionality requirements are made under section 12A of the Regulations.
- (3) Schedule 3 – Copy of an Electronic Medication Chart provides the approved information requirements to produce a copy of an electronic medication chart. Schedule 3 is only for the purposes of a chart that is used for prescribing, supplying and recording the administration of, pharmaceutical benefits to persons receiving treatment in or at an approved residential care home. The approved information requirements to produce a copy of an electronic medication chart are made under subsection 45(9) of the Regulations.

Schedule 1 – Information Requirements

Electronic Medication Chart Information Requirements - PBS/RPBS Electronic Medication Chart prescriptions for persons receiving treatment in or at an approved residential care home at which the person is receiving residential care.

1. Approved residential care home patients

- 1.1 The information requirements for a patient who is receiving residential care in an approved residential care home must include the following:
- (a) the patient's:
 - (i) full name; and
 - (ii) preferred name (if any); and
 - (iii) date of birth; and
 - (iv) gender; and
 - (v) Unit Record Number (URN) or Medical Record Number (MRN); and
 - (vi) healthcare identifier; and
 - (vii) Medicare number; and
 - (b) high resolution photograph of resident; and
 - (c) any number specified on a card, issued by the Commonwealth, as an entitlement number (however described) for the patient; and
 - (d) informed consent to treatment in line with national/state requirements; and
 - (e) patient's approved supplier including:
 - (i) full name; and
 - (ii) address; and
 - (iii) contact details sufficient to make contact with the approved supplier at any time.

2. Allergies and Drug Reactions (ADRs)

- 2.1 The information requirements for allergies and drug reactions includes the following:
- (a) the patient's allergies, including:
 - (i) drugs or other substances that cause allergic reactions; and
 - (ii) the date, type and description of each allergic reaction or a record of no allergies.
 - (b) the patient's adverse drug reactions, including:
 - (i) drugs or other substances that cause adverse drug reactions; and

- (ii) the date, type and description of each adverse drug reaction or a record of no adverse drug reactions.

3. Clinical recordings and monitoring

- 3.1 The information requirements for clinical recording and monitoring must allow for the recording of the resident's:
 - (a) weight at a point in time; and
 - (b) sedation scores.

4. Approved residential care homes

- 4.1 The information requirements for an approved residential care home must include the following details of the approved residential care home:
 - (a) business name; and
 - (b) business address; and
 - (c) Residential Aged Care Service ID.

5. Period of validity

- 5.1 The information requirements for the period of validity of the electronic medication chart must not exceed a period of six months.
- 5.2 The information requirements for the period of validity of the electronic medication chart must include the following details of the chart:
 - (a) commencement date; and
 - (b) expiry date.

6. PBS prescriber

- 6.1 The information requirements for a PBS prescriber must include the following details of the PBS prescriber:
 - (a) full name; and
 - (b) address; and
 - (c) PBS prescriber number; and
 - (d) PBS prescribers Healthcare Provider Identifier - Individual (HPI-I); and
 - (e) PBS Prescribers Healthcare Provider Identifier - Organisation (HPI-O); and
 - (f) contact details sufficient to make contact with the PBS prescriber at any time.

7. Regularly administered and short-term pharmaceutical benefits

- 7.1 The information requirements for regularly administered and short-term pharmaceutical benefits must include the following:

-
- (a) particulars sufficient to identify the pharmaceutical benefit, in line with Pharmaceutical Benefits Scheme requirements, pharmaceutical dose, form and strength; and
 - (b) the pharmaceutical benefit's:
 - (i) date and time of prescribing; and
 - (ii) dose; and
 - (iii) route of administration; and
 - (iv) frequency of administration; and
 - (v) site of administration (if appropriate); and
 - (vi) indication for prescribing; and
 - (vii) PBS Authority Approval Number/s if required; and
 - (c) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
 - (d) the start time for administration (if necessary); and
 - (e) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
 - (f) specified duration or indication that medicine is to be supplied for duration of chart; and
 - (g) brand substitution indicator
 - (h) Authority Prescription Number; and
 - (i) Closing the Gap (CTG); and
 - (j) PBS/RPBS; and
 - (k) Streamlined Authority; and
 - (l) additional instructions (if any) to be added by the medical practitioner, expressed as 'Additional Instructions'.
- 7.2 Information requirements for a regularly administered pharmaceutical benefit must also include a record of each administration of the benefit, including the following:
- (a) pharmaceutical benefit; and
 - (b) form; and
 - (c) strength; and
 - (d) dose; and
 - (e) route; and
 - (f) date and time; and
 - (g) credentials of nurse administering the pharmaceutical benefit.
- 7.3 Information requirements for a regularly administered pharmaceutical benefit must also include a record of the administration of the benefit if the benefit has been administered by means of a multi-dose pack with the date and time of administration recorded based on accepted naming conventions such as:
- (a) breakfast; or

- (b) lunch; or
- (c) dinner; or
- (d) bedtime.

8. Insulin pharmaceutical benefits (non-Pro Re Nata) (non-PRN)

- 8.1 The information requirements for a pharmaceutical benefit that is insulin and is not required to be administered PRN (as required) must include the following:
- (a) particulars sufficient to identify the pharmaceutical benefit, by active ingredient and brand name, form, strength and units; and
 - (b) the pharmaceutical benefit's:
 - (i) date and time of prescribing; and
 - (ii) route of administration; and
 - (iii) time for administration; and
 - (iv) PBS Authority Approval Number/s (if required); and
 - (c) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
 - (d) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
 - (e) specified duration or indication that medicine is to be supplied for duration of chart; and
 - (f) Authority Prescription Number; and
 - (g) Closing the Gap (CTG); and
 - (h) PBS/RPBS; and
 - (i) additional instructions (if any) to be added by the medical practitioner, expressed as 'Additional Instructions'; and
 - (j) Blood Glucose Level (BGL) range for administration; and
 - (k) Blood Glucose Level recording and charting of:
 - (i) date and time; and
 - (ii) Blood Glucose Level.
- 8.2 Information requirements for a regularly administered pharmaceutical benefit must also include a record of each administration of the benefit including the following:
- (a) date and time; and
 - (b) units/dose; and
 - (c) credentials of the first nurse authorising and administering the pharmaceutical benefit; and
 - (d) credentials of the second nurse authorising and administering the pharmaceutical benefit.

9. Insulin PRN (as required) pharmaceutical benefits

- 9.1 The information requirements for a pharmaceutical benefit that is insulin required to be administered PRN (as required) must include the following:
- (a) particulars sufficient to identify the pharmaceutical benefit, by active ingredient and brand name, form, strength and units; and
 - (b) the pharmaceutical benefit's:
 - (i) date and time of prescribing; and
 - (ii) route of administration; and
 - (c) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
 - (d) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
 - (e) specified duration or indication that medicine is to be supplied for duration of chart; and
 - (f) Closing the Gap (CTG); and
 - (g) PBS/RPBS; and
 - (h) the maximum dose in 24 hours; and
- 9.2 Information requirements for a regularly administered pharmaceutical benefit must also include a record of each administration of the benefit including the following:
- (a) date and time; and
 - (b) units/dose; and
 - (c) Blood Glucose Level recording and charting of:
 - (i) date and time; and
 - (ii) Blood Glucose Level.
 - (d) credentials of the first Nurse authorising and administering the pharmaceutical benefit.

10. PRN (as required) pharmaceutical benefits

- 10.1 The information requirements for a pharmaceutical benefit, other than insulin, that is required to be administered PRN (as required) must include the following:
- (a) particulars sufficient to identify the pharmaceutical benefit, in line with Pharmaceutical Benefits Scheme Prescribing requirements, pharmaceutical dose, form and strength; and
 - (b) the pharmaceutical benefit's:
 - (i) date and time of prescribing; and
 - (ii) dose; and
 - (iii) route of administration; and
 - (iv) frequency of administration; and

- (v) site of administration (if appropriate); and
 - (vi) indication for prescribing; and
 - (vii) PBS Authority Approval Number/s if required; and
 - (c) the indication for administration of the pharmaceutical benefit; and
 - (d) maximum individual dose or range; and
 - (e) minimum interval between administrations; and
 - (f) maximum dose in 24 hours; and
 - (g) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
 - (h) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
 - (i) specified duration or indication that medicine is to be supplied for duration of chart; and
 - (j) brand substitution indicator; and
 - (k) Authority Prescription Number; and
 - (l) Closing the Gap (CTG); and
 - (m) PBS/RPBS; and
 - (n) Streamlined Authority; and
 - (o) additional instructions (if any) to be added by the medical practitioner, expressed as 'Additional Instructions'.
- 10.2 Information requirements for a regularly administered pharmaceutical benefit must also include a record of each administration of the benefit including:
- (a) pharmaceutical benefit; and
 - (b) form; and
 - (c) strength; and
 - (d) dose administered; and
 - (e) route; and
 - (f) reason for administration of the pharmaceutical benefit; and
 - (g) date and time; and
 - (h) credentials of Nurse administering the pharmaceutical benefit; and
 - (i) outcome or effect of medicine and time observation was made; and
 - (j) credentials of Nurse recording the observation.

11. Variable dose pharmaceutical benefits (non-insulin)

- 11.1 The information requirements for a pharmaceutical benefit, other than insulin, that is required to be administered at a variable dose must include the following:

- (a) particulars sufficient to identify the pharmaceutical benefit, in line with Pharmaceutical Benefits Scheme Prescribing requirements, pharmaceutical dose, form and strength; and
 - (b) the pharmaceutical benefit's:
 - (i) date and time of prescribing; and
 - (ii) dose; and
 - (iii) route of administration; and
 - (iv) frequency of administration; and
 - (v) site of administration (if appropriate); and
 - (vi) indication for prescribing; and
 - (vii) PBS Authority Approval Number/s if required; and
 - (c) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
 - (d) the start time for administration (if necessary); and
 - (e) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
 - (f) specified duration or indication that medicine is to be supplied for duration of chart; and
 - (g) brand substitution indicator; and
 - (h) Authority Prescription Number; and
 - (i) Closing the Gap (CTG); and
 - (j) PBS/RPBS; and
 - (k) Streamlined Authority; and
 - (l) additional instructions (if any) to be added by the medical practitioner, expressed as 'Additional Instructions'.
- 11.2 Information requirements for a regularly administered pharmaceutical benefit must also include a record of each administration of the benefit with the following details:
- (a) pharmaceutical benefit; and
 - (b) form; and
 - (c) strength; and
 - (d) dose; and
 - (e) route; and
 - (f) date and time; and
 - (g) dose administered; and
 - (h) credentials of the first nurse authorising and administering the pharmaceutical benefit; and
 - (i) credentials of the second nurse authorising and administering the pharmaceutical benefit.

12. Infusion pharmaceutical benefit additional requirements

- 12.1 The additional information requirements for prescribing of a pharmaceutical benefit that is an infusion must include additional instructions to be added by the medical practitioner, expressed as 'Additional Instructions' to capture information of the pharmaceutical benefit, such as:
- (a) infusion instructions; and
 - (b) infusion liquid; and
 - (c) rate/time; and
 - (d) maximum hourly rate; and
 - (e) daily limits; or
- 12.2 The system functionality requirements covered in paragraph 9 of Schedule 2 of this instrument.

13. Transdermal Patch pharmaceutical benefit additional requirements

- 13.1 The additional information requirements for prescribing of a pharmaceutical benefit that is a Transdermal Patch must include additional instructions to be added by the medical practitioner, expressed as 'Additional Instructions' to capture information of the pharmaceutical benefit, such as:
- (a) day for application; and
 - (b) instructions for safe removal; and
 - (c) placement of patch; and
 - (d) minimum 'patch free' time.

14. Schedule 8 (controlled) pharmaceutical benefits additional requirements

- 14.1 The additional information requirements for prescribing and administration of a Schedule 8 (controlled) pharmaceutical benefit must include the credentials of the second nurse authorising and administering the pharmaceutical benefit

15. Nutritional supplements pharmaceutical benefits

- 15.1 The information requirements for a pharmaceutical benefit that is a nutritional supplement must include the following:
- (a) particulars sufficient to identify the pharmaceutical benefit, including the name and strength, expressed as 'nutritional supplement'; and
 - (b) the pharmaceutical benefit's:
 - (i) date of prescribing; and
 - (ii) dose; and
 - (iii) route of administration; and

- (iv) frequency of administration; and
- (v) Indication for use (when relevant); and
- (c) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
- (d) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
- (e) specified duration or indication that medicine is to be supplied for duration of chart; and
- (f) brand substitution indicator; and
- (g) Closing the Gap (CTG); and
- (h) PBS/RPBS; and
- (i) additional instructions (if any) to be added by the PBS prescriber, expressed as 'Additional Instructions'.

Schedule 2 – System Functionality

Electronic Medication Chart System Functionality - PBS/RPBS Electronic Medication Chart prescriptions for persons receiving treatment in or at an approved residential care home at which the person is receiving residential care.

1. Approved residential care home patients

- 1.1 The system functionality for a patient who is receiving residential care in or at an approved residential care home must:
- (a) alert for consumers with similar-sounding names; and
 - (b) ensure that the resident's details include all details listed in paragraph 1.1 of Schedule 1 of this instrument, and are visible on all system screens from which medicines are prescribed, reviewed, supplied or administered.

2. Allergies and Drug Reactions (ADRs)

- 2.1 The system functionality allergies and adverse reactions for a patient who is receiving residential care in an or at approved residential care home must:
- (a) allow the user to record administration-related ADRs; and
 - (b) ensure that allergies and ADRs are visible on all system screens from which medicines are prescribed, reviewed, supplied or administered.

3. Period of validity

- 3.1 The system functionality for the six month period of validity of the electronic medication chart must:
- (a) alert all users when chart is nearing expiry - at least three weeks before expiry; and
 - (b) not allow for further prescribing, supply or administration of pharmaceutical benefits past the expiry date.

4. PBS prescriber

- 4.1 The system functionality for a PBS prescriber must:
- (a) validate the PBS Prescribers Australian Health Practitioner Regulation Agency (AHPRA) number; and
 - (b) validate the PBS Prescribers Healthcare Provider Identifier - Individual (HPI-I); and
 - (c) validate the PBS Prescribers Healthcare Provider Identifier - Organisation (HPI-O).

5. Regularly administered and short-term pharmaceutical benefits

- 5.1 The system functionality for a regularly administered and short-term pharmaceutical benefit must ensure:
- (a) that systems that do not default to add Brand; and
 - (b) for short-term medicines, that the system must only enable administration for the duration specified by the prescriber.

6. Insulin pharmaceutical benefits (non-PRN)

- 6.1 The system functionality for pharmaceutical benefit that is insulin and is not required to be administered PRN (as required) must not default to add Brand.

7. PRN (as required) pharmaceutical benefits

- 7.1 The system functionality for PRN pharmaceutical benefits must ensure that systems must not default to add Brand.

8. Variable dose pharmaceutical benefits (non-insulin)

- 8.1 The system functionality for a pharmaceutical benefit, other than insulin, that is required to be administered at a variable dose must:
- (a) enable prescribing based on:
 - (i) age; and
 - (ii) weight; and
 - (b) capture the dates that dose changes will apply; and
 - (c) support variable dosing regimens including tapering regimens and dose rounding; and
 - (d) must not default to add Brand.

9. Infusion pharmaceutical benefits

- 9.1 The system functionality requirements for prescribing of a pharmaceutical benefit that is an infusion must include:
- (a) indicator to notify when an infusion chart outside of the eNRMC chart is active for the resident; and
 - (b) additional instructions field to be added by the medical practitioner, expressed as 'Additional Instructions' to capture information and details, such as the infusion chart type.
- 9.2 If section 12.1 of Schedule 1 applies, Section 9.1 does not apply.

10. Schedule 8 (controlled) pharmaceutical benefits

- 10.1 The system functionality for a Schedule 8 (controlled drugs) pharmaceutical benefit must:

- (a) restrict prescribing of pharmaceutical benefit to maximum quantity as per the Regulations; and
- (b) restrict prescribing and supply of pharmaceutical benefits as per the Regulations and not be permitted for duration of the medication chart.

11. Security and Validation

11.1 The Security and Validation system functionality for electronic medication charts must:

- (a) maintain audit log records of all medication management transactions, including the following:
 - (i) all changes to medicine orders, and the dose and route of the administered medicine; and
 - (ii) all changes to annotations; and
 - (iii) the date and time of each transaction; and
 - (iv) the name, designation and registration number of the user undertaking each transaction; and
- (b) ensure all medicine orders and changes to them can be audited and attributed to the person(s) who made the changes.

12. Additional System Functionality

12.1 The additional system functionality requirements for electronic medication charts must include the following:

- (a) ensure all suppliers (contracted and non-contracted) have access to the full list of medicine orders on the electronic medication chart in real time; and
- (b) systems must only display current medicines and ceased medicines for the current medication chart duration; and
- (c) enable generation of a copy of an electronic medication chart which:
 - (i) meets information requirements as specified by the Secretary; and
 - (ii) each page is date and time stamped.

Schedule 3 – Copy of an Electronic Medication Chart

Copy of a Medication Chart Information Requirements to support supply from a copy of a PBS/RPBS Electronic Medication Chart prescription for persons receiving treatment in or at an approved residential care home at which the person is receiving residential care, in urgent situations.

1. Approved residential care home patients

- 1.1 The copy of a chart requirements for a patient who is receiving residential care in or at an approved residential care home must include the patient's:
- (a) full name; and
 - (b) date of birth; and
 - (c) healthcare identifier; and
 - (d) Medicare number; and
 - (e) any number specified on a card, issued by the Commonwealth, as an entitlement number (however described) for the patient; and
 - (f) weight.

2. Allergies and Drug Reactions (ADRs)

- 2.1 The copy of a chart requirements for allergies and drug reactions must be easily readable and clearly visible to a person looking at any page of the medication chart, and must include the following:
- (a) the patient's allergies, including:
 - (i) drugs or other substances that cause allergic reactions; and
 - (ii) the date, type and description of each allergic reaction; and
 - (b) the patient's adverse drug reactions, including:
 - (i) drugs or other substances that cause adverse drug reactions; and
 - (ii) the date, type and description of each adverse drug reaction.

3. Approved residential care homes

- 3.1 The copy of a chart requirements for an approved residential care home must include the following details of the approved residential care home:
- (a) business name; and
 - (b) business address; and

- (c) Residential Aged Care Service ID.

4. Current Pharmaceutical Benefits

- 4.1 The copy of a chart requirements for current pharmaceutical benefits is provided below:
 - (a) The information for a regularly administered pharmaceutical benefit must include:
 - (i) particulars sufficient to identify the pharmaceutical benefit, including the name, pharmaceutical dose, form and strength, expressed as 'medicine/form/strength'; and
 - (ii) date of prescribing; and
 - (iii) dose; and
 - (iv) route of administration; and
 - (v) frequency of administration; and
 - (vi) prescriber details to satisfy paragraph 6 of Schedule 1
 - (b) The information for a PRN administered pharmaceutical benefit must include:
 - (i) particulars sufficient to identify the pharmaceutical benefit, including the name, pharmaceutical dose, form and strength, expressed as 'medicine/form/strength'; and
 - (ii) date of prescribing; and
 - (iii) dose; and
 - (iv) maximum dose in 24hr; and
 - (v) route of administration; and
 - (vi) frequency of administration; and
 - (vii) prescriber details to satisfy Schedule 1 paragraph 4.
 - (c) The information for a short-term pharmaceutical benefit must include:
 - (i) particulars sufficient to identify the pharmaceutical benefit, including the name, pharmaceutical dose, form and strength, expressed as 'medicine/form/strength'; and
 - (ii) date of prescribing; and
 - (iii) dose; and
 - (iv) route of administration; and
 - (v) frequency of administration; and
 - (vi) prescriber details to satisfy paragraph 6 of Schedule 1.
 - (d) The information for a variable dose pharmaceutical benefit must include:
 - (i) particulars sufficient to identify the pharmaceutical benefit, including the name, pharmaceutical dose, form and strength, expressed as 'medicine/form/strength'; and
 - (ii) date of prescribing; and

- (iii) dose; and
- (iv) route of administration; and
- (v) frequency of administration; and
- (vi) prescriber details to satisfy paragraph 6 of Schedule 1.

5. Recently Ceased Pharmaceutical Benefits

- 5.1 The copy of a chart requirements for recently ceased pharmaceutical benefits within the current chart duration must include the following:
- (a) particulars sufficient to identify the pharmaceutical benefit, including the name, pharmaceutical dose, form and strength, expressed as 'medicine/form/strength'; and
 - (b) dose; and
 - (c) route of administration; and
 - (d) frequency of administration; and
 - (e) prescriber details to satisfy paragraph 6 of Schedule 1; and
 - (f) date ceased; and
 - (g) reason for cessation (if known).

6. Pharmaceutical Benefit Administration

- 6.1 The copy of a chart requirements for all pharmaceutical benefit administration must include the following:
- (a) commencement date; and
 - (b) cessation date; and
 - (c) administration considerations.

7. Nutritional Supplements

- 7.1 The copy of a chart requirements for a pharmaceutical benefit that is a nutritional supplement must include the following:
- (a) particulars sufficient to identify the pharmaceutical benefit, including the name and strength, expressed as 'nutritional supplement'; and
 - (b) date of prescribing; and
 - (c) dose; and
 - (d) route of administration; and
 - (e) frequency of administration; and
 - (f) prescriber details to satisfy paragraph 6 of Schedule 1.

8. Period of validity

- 8.1 For the 72-hour period of validity of a copy of an electronic medication chart, each page of the copy must include the following details of the chart:

- (a) commencement time and date; and
- (b) expiry time and date.

9. Medication Chart and Medication Chart Order Identification

- 9.1 The copy of a chart requirements for a medication chart must include the chart identifier.
- 9.2 The copy of a chart requirements for a medication chart order must include:
 - (a) an identifier for each individual medication chart order represented as a token in the form of:
 - (i) DSPID in alpha numeric form; and
 - (ii) barcode; or QR code.

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnotes

Endnote 2—Abbreviation key

Endnote 2—Abbreviation key

ad = added or inserted	orig = original
am = amended	p = page(s)
amdt = amendment	para = paragraph(s)/subparagraph(s) /sub-subparagraph(s)
C[x] = Compilation No. x	pres = present
ch = Chapter(s)	prev = previous
cl = clause(s)	(prev...) = previously
cont. = continued	pt = Part(s)
def = definition(s)	r = regulation(s)/Court rule(s)
Dict = Dictionary	reloc = relocated
disallowed = disallowed by Parliament	renum = renumbered
div = Division(s)	rep = repealed
ed = editorial change	rs = repealed and substituted
exp = expires/expired or ceases/ceased to have effect	s = section(s)/subsection(s) /rule(s)/subrule(s)/order(s)/suborder(s)
gaz = gazette	sch = Schedule(s)
LA = <i>Legislation Act 2003</i>	SLI = Select Legislative Instrument
LIA = <i>Legislative Instruments Act 2003</i>	SR = Statutory Rules
(md) = misdescribed amendment can be given effect	sub ch = Sub-Chapter(s)
(md not incorp) = misdescribed amendment cannot be given effect	sub div = Subdivision(s)
mod = modified/modification	sub pt = Subpart(s)
No. = Number(s)	<u>underlining</u> = whole or part not commenced or to be commenced
Ord = Ordinance	

Endnote 3—Legislation history

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Pharmaceutical Benefits) Electronic National Residential Medication Charts Approval Instrument 2025 (PB 48 of 2025)	30 June 2025 (F2025N00483)	1 July 2025 (s 2)	
National Health (Pharmaceutical Benefits) Electronic National Residential Medication Charts Amendment (Aged Care Legislation) Approval Instrument 2025 (PB 132 of 2025)	17 Nov 2025 (F2025N00906)	1 Nov 2025 (s 2(1) item 1)	—

Endnotes

Endnote 4—Amendment history

Endnote 4—Amendment history

Provision affected	How affected
s 2.....	rep LA s 48D
s 4.....	am F2025N00906
s 5.....	am F2025N00906
s 6.....	rep LA s 48C
Schedule 1	
Schedule 1.....	rs F2025N00906
Schedule 2	
Schedule 2.....	rs F2025N00906
Schedule 3	
Schedule 3.....	rs F2025N00906
Schedule 4.....	rep LA s 48C
